Synaptogenix, Inc. — Form 10-Q Summary
Filing identity: The supplied filing is for Synaptogenix, Inc. (Nasdaq: SNPX), not TAO Synergies Inc. The filing covers the quarter and six months ended June 30, 2022; it was signed August 5, 2022. Financial statements are unaudited.
Business context and reporting period
Synaptogenix is a clinical-stage biopharmaceutical company primarily developing Bryostatin-1 for Alzheimer’s disease (AD), with potential programs in Fragile X syndrome, multiple sclerosis and other disorders. It reported no revenue and continues to fund research and development through cash reserves and financing activities.
Financial results and liquidity
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $1.94 million | $3.43 million | $0.99 million and $2.14 million, respectively |
| General and administrative expense | $1.86 million | $3.65 million | $1.31 million and $3.31 million, respectively |
| Total operating expenses | $3.80 million | $7.08 million | $2.30 million and $5.45 million, respectively |
| Net loss | $3.75 million | $7.03 million | $2.29 million and $5.45 million, respectively |
| Basic and diluted loss per share | $0.54 | $1.01 | $0.58 and $1.53, respectively |
- Six-month operating cash outflow was $6.01 million, versus $5.59 million in 2021. Investing cash outflow was $3,029; financing cash inflow was $553,150, primarily from warrant exercises.
- Cash and cash equivalents were $28.75 million at June 30, down from $34.21 million at December 31, 2021. Management reported approximately $27.4 million in cash as of the filing and expected it to fund projected operating requirements for at least 12 months from the filing date.
- Working capital was $28.93 million, compared with $33.51 million at year-end 2021. Current liabilities were $626,000; the balance sheet reported no debt. No gross margin is reported because the company had no revenue.
- Stockholders’ equity was $28.95 million, down from $33.53 million at year-end. The company reported an accumulated deficit of $21.17 million.
Material changes versus the prior comparable period
- Six-month net loss increased 29% year over year; second-quarter net loss increased 64%. Higher clinical-trial and other R&D spending, along with higher noncash stock-based compensation, contributed to the increases.
- Six-month R&D expense rose 60%; second-quarter R&D expense rose 97%. Six-month G&A increased 10%, while second-quarter G&A increased 42%.
- Cash declined by $5.46 million during the first half of 2022. Unlike 2021, when private placements generated substantial financing proceeds, first-half 2022 financing proceeds were limited to warrant exercises.
Outlook, risks and unusual items
- The company expected its existing AD Phase 2 trial to be materially concluded by year-end 2022 and anticipated top-line data in the fourth quarter of 2022. It also began an open-label, dose-ranging Phase 2 study, planned for approximately 12 participants, with an estimated budget of about $2.0 million. Enrollment was underway; the first site opened in the third quarter of 2022.
- The existing Phase 2 trial’s estimated total budget was about $12.0 million, with approximately $9.4 million in cumulative expenses reported by June 30. The company had received the maximum reimbursements available under its $2.7 million NIH grant.
- Management said further capital would be needed for additional development, including continuing Bryostatin-1 development beyond the ongoing trial. Future financing may be unavailable or dilutive, and licensing or collaboration could require giving up product rights.
- A prior confirmatory Phase 2 study did not meet its primary endpoint; the reported post-hoc moderate-stratum analysis also did not show a statistically significant difference between treatment and placebo. Clinical efficacy remains uncertain.
- Supply is a risk: the NCI agreement does not provide enough bryostatin for all trials needed to seek FDA approval, and additional supply arrangements may be required. The company also identified potential COVID-related trial delays and vendor or supplier disruption.
- Disclosure controls and procedures were reported ineffective due to material weaknesses involving segregation of duties, period-end reporting and documentation, and IT general controls. Management nevertheless stated that the financial statements fairly present the company’s financial position and results in all material respects.
- The filing disclosed uncapped indemnification obligations related to the separation from Neurotrope, including tax-related exposures; no indemnification claims or liabilities were reported as of the filing. No legal proceedings were reported.
- Subsequent to quarter-end, the CEO’s employment term was extended through June 7, 2023, with six months’ salary severance for termination without cause.
Important facts for investors to verify
- Confirm that Synaptogenix, rather than TAO Synergies Inc., is the intended filing and issuer.
- Review the timing and results of the ongoing AD trials, including the anticipated fourth-quarter 2022 top-line data, and assess how prior trial results affect the development case.
- Assess the cash runway against trial budgets, expected spending and the company’s stated need for additional capital.
- Verify the availability and adequacy of bryostatin supply for planned trials and the status of alternative supply arrangements.
- Monitor remediation of the disclosed control weaknesses and evaluate the potential exposure from uncapped separation-related indemnities.